Meadowhawk Biolabs
Overview
Meadowhawk Biolabs is a contract research organization (CRO) specializing in drug discovery, pharmacology, and bioanalytical services. Founded in 2021, the company operates from its headquarters in Marlborough, Massachusetts, with an additional facility in Hayward, California. Meadowhawk Biolabs has quickly established itself in the industry, raising approximately $20.2 million through a series of funding rounds. The company is led by CEO Jim Jersey, who along with a team of experienced professionals, provides critical services tailored to the pharmaceutical and biotech sectors.
Recent Developments
- March 2024: Meadowhawk Biolabs filed for a new equity investment of $6 million to further its research capabilities.
- July 2024: Secured $5 million in Series A funding, continuing to bolster its financial foundation to support expanding operations both domestically and internationally.
- April 2024: Launched an updated marketing strategy with a focus on digital presence and community engagement to enhance brand visibility and lead generation, resulting in a notable increase in web traffic and social media following.
- 2023: Meadowhawk has been rolling out advanced bioanalytical services, including liquid chromatography-mass spectrometry (LC/MS), aimed at enhancing their service penetration within the biomarker and clinical development sectors.
- 2022: Introduced new service lines focusing on non-GLP bioanalysis and in vivo pharmacokinetic services for both small and large molecule drugs. These services aim to facilitate more flexible drug discovery solutions.
- 2025 Activity: The company has maintained active participation in industry events such as the Advances in Chemical Sciences Symposium, showcasing its commitment to scientific community engagement and networking.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2021 |
| Headquarters | Marlborough, Massachusetts, USA |
| Founders | Jim Jersey (CEO) and team |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Ampersand Capital |
| Industry | Biotechnology Research |
| Number of Employees | 11-50 |
Early History
Meadowhawk Biolabs was founded in 2021 by a group of industry experts, primarily veterans from Agilux Laboratories. The founding team brought with them substantial experience in bioanalytical services, laid the groundwork for Meadowhawk to emerge as a competitive entity in contract research. Initially, the company focused on establishing its core competencies in drug discovery and bioanalytical services. The early investments were directed towards equipping the laboratories with cutting-edge tools like LCMS instruments, essential for conducting high-quality analysis. By mid-2021, Meadowhawk had secured its first round of funding, injecting significant capital for expansion and operational scaling.
Company Profile and Achievements
Meadowhawk Biolabs offers a range of services tailored specifically to meet the nuanced needs of pharmaceutical companies and biotech firms. Its business model centers around flexibility and scientific excellence, providing bespoke CRO solutions rather than generic options.
- Service Specialization: Offers services such as In Vivo studies, quantitative bioanalysis for both small and large molecules, and an array of exploratory and IND-enabling services.
- Achievements: Rapidly gained traction in the CRO sector by supporting high-stakes drug discovery projects efficiently and effectively.
- Recognition: The company has been acknowledged for its innovative operational model which combines scientific insight with advanced process engineering to speed up research outcomes.
- Expansion Efforts: Expedited early drug discovery processes by establishing bi-coastal facilities for quicker and more adaptable deployment of services.
Current Operations and Market Position
Operating primarily as a CRO, Meadowhawk Biolabs continues to expand its market influence with a focus on drug discovery and bioanalytical services. Its services cater to both small molecule and large molecule modalities. Meadowhawk has managed to carve out a niche by avoiding a one-size-fits-all approach, opting instead for tailored service offerings. It has a significant focus on networking and fostering relations within the scientific community, enhancing its market position through thought leadership and sponsorship of significant scientific symposia. The firm ranks among the top competitors like Evotec and Crown Bioscience, albeit with a smaller but rapidly growing client portfolio.
Conclusion
Meadowhawk Biolabs stands as a promising entity within the biotechnology research industry due to its innovative approach and focus on custom-tailored contract research services. By leveraging the expertise of its founding members and engaging aggressively in industry partnerships and events, Meadowhawk aims to continue its trajectory of growth and influence. Looking ahead, the company's strategic positioning and financial backing from key investors could set a path towards significant advancements in drug discovery and related CRO services, potentially expanding its footprint further both domestically and internationally.